Wednesday, October 17, 2012

RS Sell Thesis

Today we sold all of our 90 shares of Reliance Steel (RS) at the price of $53.52. This represents a loss of 3.85%. The company continues to do well, but it is not reflective in their stock price. This is a great example of a great company, but a bad stock. We bought in at the tail end of a 40% upswing and the stock plateaued after we bought it. The thesis when we originally bought this stock was based on improving steel demand and steel pricing. While this thesis held true for a few months, it turned for the worse and the steel industry as a whole suffered. The steel industry currently is not doing well due to a very high supply, but weakening  demand. This is driving prices down which is hurting all companies throughout the industry. A big driver of the industry is China because they have a very high demand for steel. With their economy currently slowing, it is hurting the steel industry as whole, even companies with minimal exposure such as Reliance Steel. RS has beat estimates for the first and second quarters of this year, but in the last conference call, management lowered guidance for the second half of the year, which was slightly below the streets estimates. So I felt as if this was a good time to sell out with minimal losses. The stock usually does better in the first two quarters and then regresses. If the stock becomes favorable again at a lower price before the first quarter of 2013, it may be a good opportunity to buy back in.

-John Astarita

Friday, October 12, 2012

OZRK Q3 Earnings

OZRK released earnings last night after market close. Net Income was 19.3 million, up 2% from Q3 last year. EPS was .55, in line with estimates and unchanged from last year. Legacy loan portfolio grew 9.1% to 2.03 billion from 1.86 billion while total loans (including loss share loans) dropped 1.4%. Deposits were down 5.1% to 2.89 billion Assets were 3.82 billion down from 3.93 billion Q3 2011. Stockholders' equity was up 17.4% to 478 million. Net interest income was up only .2% to $44.4 million over last year. Non-interest income declined almost 10% to 14.5.
Over all, these results are not fantastic, but not bad. The market responded with a 4% drop in price today. I will incorporate these into my model, but I don't forsee a significant change in my target price of $35.77. I believe the market got overly excited after last quarter's performance and had anticipations a little too high, and I believe the stock will rebound.

Honeywell acquisition of Thomas Russell

UOP, a Honeywell company in their Performance Materials and Technologies sector, recently acquired a 70% stake in Thomas Russell Co. for $525 million and also have rights to purchase the remaining 30%, which raised its involvement in natural gas processing.  Thomas Russel was a privately held, leading provider of technology and equipment for natural gas and processing and treatment.  With this acquisition, Honeywell will be able to provide shale and conventional natural gas companies with a broad range of technology and equipment to remove contaminants from natural gas and produce high quality natural gas liquids used for petrochemical and fuel.

This is a significant purchase in that they are investing the natural gas market and seeing the possibilities of growth.  With the agreement between ConocoPhillips, BP and TransCanada Corp. of building the pipeline between Alaska and Asia, this is definitely an emerging market that has much prospect for future growth.  Natural gas is not just showing growth for a few years ahead but rather for decades to come so I feel very positive about Honeywell's actions of trying to break into this market.  After this acquisition, Dave Cote stated in an interview, "We will keep making acquisitions in natural gas and invest in the UOP unit to develop new gas technology," Cote said, "I'm a big believer in natural gas and in what it can do for the U.S. economy and many economies around the world." With this, I see Honeywell only as a hold rather than a buy currently, as the UOP division is still only a small segment of their whole enterprise.

Thursday, October 4, 2012

OZRK Acquisition of Genala Bank

OZRK announced after market close today that they have entered into a $27.3 million agreement with Genala Bank which operates The Citizens Bank (not to be confused with Citizen's Bank), a one-office bank in Geneva, Alabama.This announcement marks a first for Ozarks as it is not an FDIC-assisted acquisition, but rather that of traditional M&A. OZRK CEO called the company "a healthy bank with solid market share," which makes for an entirely different situation from the failed banks they have purchased in recent years. OZRK will be issuing $13.9 million in stock and paying $13.4 million cash in exchange for all outstanding Genala shares. As of Q2 2012, Genala carried approximately $170 million in total assets, $45 million in loans, and $142 million deposits on its balance sheet. However, other financial statement information is not available. This transaction is expected to close late December of this year or early Q1 2013. This acquisition was unanimously approved on both sides.

OZRK has a history of making sound decisions and investments, and clearly they believe that this will have a net benefit to the company, but this is a difficult transaction to analyze. Very much on the surface, OZRK is exchanging $27.3 million in assets and equity for $28 million in net assets, which sounds like a good deal. However, a lot of information is not available, like the quality of the loan underwriting and the deposit mix can make a huge difference. Having deposits more than 3x loans has to be a significant drag on net interest income and margin. The combined Q2 balance sheet represents $3.9 billion assets with $2.7 billion loans and $2.9 billion deposits, which is 1.08x loans. On their own, OZRK's deposits are 1.06x loans and their net interest margin significantly surpasses peers at almost 6% (most peers weigh in around 3.5%), which is even more impressive in the current interest rate environment. With OZRK's size, I think the loan/deposit mix is still reasonably balanced, although I certainly expect some negative impact on net interest income and margin.

I expect a dip in OZRK share price tomorrow in response to the news, but I think it will be largely superficial, particularly considering that OZRK reports Q3 earnings next Thursday. Last quarter, OZRK stock climbed nearly 9% in the day following earnings. This timing is advantageous, and no doubt strategic.

Without more information, I am not sure whether to anticipate net gains or losses from this acquisition, although I expect net gains are far more likely. OZRK closed at 34.12 and my current price target is 35.77, although that will be revised post-earnings. I certainly maintain my hold position through the earnings release, at which point the model will be updated and the price target revised.

Thursday, September 20, 2012

Boston Scientific to acquire BridgePoint Medical

     Boston Scientific (BSX) announced its intention to acquire BridgePoint Medical, a privately-held medical device company. The purchase price has not yet been disclosed, but the deal is expected to close by year end. BridgePoint Medical is the producer of catheters used for blood flow restoration in patients with coronary chronic total occlusions (CTO). BridgePoint's product line up, including the Crossbow and Stringray systems, allows patients to forgo invasive bypass surgery and and avoid long recovery periods. Under BridgePoint's CTO system, some patients may return home in as little as 24 hours.
  
     Overall, the acquisition of the CTO product lineup is consistent with BSX's goal to be a leading producer of interventional cardiology products. Over 500,000 coronary bypass surgeries are performed each year, and the Crossbow and Stringray products offer a less invasive alternative. More information on the valuation of BridgePoint is needed to fully understand the acquisition, but it is not expected to be accretive until after fiscal year 2013. Since the announcement, BSX has been relatively flat, trading up 50 bps to $5.81 versus broader market losses of 10 bps.

Wednesday, September 5, 2012

NVDA's Downgrade by Evercore Partners (09/04/12)

Shares of NVIDIA Corporation fell  5.38% after Evercore Partners Inc. downgraded the maker of graphics processors to underweight from equal-weight and lowering PT to 13$, saying 2013 will be “challenging” for the company.  According to Evercore Partners, Apple’s launch of the IPad mini and new IPad might be a serious threat to Tegra-based tablets. In addition to that, the upcoming  Nexus 10 might switch from using Nvidia’s Tegra 3 chip to Samsung Electronics Co.’s Exynos 5. This might lead to inventory buildup in the next few months.
 However, there are few important things that have to be mentioned in regards to Evercore’s research. Nvidia is just starting to ramp production for its Chinese smartphone design wins. While growth has slowed dramatically in China, this is still a very large market, and one where Wall Street tends to have limited visibility (especially outside of the major coastal metropolises). With Tegra designed into 13 phones priced at $300 or less sales volume in China will likely outweigh more visible disappointments. Besides that, IPad Mini threat might be overstated, since it will be hard for Apple to match competitors’ prices; anything lower than $249 for the tablet will hurt Apple’s margins.  On the last conference call NVIDIA’s CEO made a point that Android tablets will be sold primarily to Android phone users.  Perhaps some Android phone users will pay a premium for the iPad Mini over an Android tablet, but the majority will stay within the Android ecosystem, for reasons of convenience. Also, Nvidia won the MacBook Pro GPU slot back from AMD this year, with the help of its new "Kepler" line of GPUs. Indeed, the introduction of Kepler is helping Nvidia gain market share from AMD across PC manufacturers. Nvidia's Q2 results indicate that share gains outweigh weak PC sales thus far, and can provide earnings upside even in a soft market.
 In order to reassess our position in NVIDIA we will focus in the next couple of days in updating our valuation and also perform supply chain analysis for NVIDIA and its customers.

Wednesday, August 29, 2012

AEO 2Q12 Earnings 8/20/12


     American Eagle Outfitters released earnings for 2Q12 on August 20th, 2012.  They reported net sales of $740mil compared to $669mil in 2Q11, which represents an 11% increase year-over-year, and beats street expectations of $738mil.  Sales were driven by a 9% increase in comparable store sales, and an increase in the average selling price. The company's AE Brand, aerie and AEO Direct segments reported a growth of 7%, 13% and 28%, respectively, in comparable store sales.  An adjusted EPS of 21 cents marks a 62% increase in EPS year-over-year.  Gross margin improved 210 basis points to 37.4%. Increase in margin was driven by strong top-line growth, lower product costs, and a decrease in occupancy/warehousing expenses.  AEO opened 9 new stores (8 of which are outlet stores), in 2Q12, and also closed 8 locations during the same period.

     EPS estimate for the third quarter is between 37 – 38 cents, which is higher than EPS from 2Q11 of 30 cents.  For the year, adjusted EPS is expected to be $1.33 to $1.36 which assumes comp store sales growth in the mid single-digit range. Guidance is adjusted for the 10 cent per share 77kids operating loss due to the closing of that business. The sale of the 77kids business was closed late in the quarter, and is expected to cause an after-tax loss of $35mil, of which $9mil is expected to be incurred in 3Q12.